BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20348204)

  • 1. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24.
    Banerjee R; Huang Y; McNamee JP; Todorova M; Jean-Claude BJ
    J Pharmacol Exp Ther; 2010 Jul; 334(1):9-20. PubMed ID: 20348204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle.
    Banerjee R; Huang Y; Qiu Q; McNamee JP; Belinsky G; Jean-Claude BJ
    Cell Signal; 2011 Apr; 23(4):630-40. PubMed ID: 21138763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.
    Al-Safadi S; Domarkas J; Han Y; Brahimi F; Jean-Claude BJ
    Anticancer Drugs; 2012 Jun; 23(5):483-93. PubMed ID: 22421369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
    Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
    J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.
    Brahimi F; Rachid Z; McNamee JP; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
    Biochem Pharmacol; 2005 Aug; 70(4):511-9. PubMed ID: 15982640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species.
    Todorova MI; Larroque AL; Dauphin-Pierre S; Fang YQ; Jean-Claude BJ
    Mol Cancer Ther; 2010 Apr; 9(4):869-82. PubMed ID: 20354119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
    Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
    J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.
    Heravi M; Rachid Z; Goudarzi A; Schlisser A; Jean-Claude BJ; Radzioch D; Muanza TM
    Anticancer Drugs; 2009 Sep; 20(8):659-67. PubMed ID: 19581798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line.
    Banerjee R; Rachid Z; Qiu Q; McNamee JP; Tari AM; Jean-Claude BJ
    Br J Cancer; 2004 Sep; 91(6):1066-73. PubMed ID: 15365562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.
    MacPhee M; Rachid Z; Todorova M; Qiu Q; Belinsky G; Jean-Claude BJ
    Invest New Drugs; 2011 Oct; 29(5):833-45. PubMed ID: 20428924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
    Matheson SL; McNamee JP; Jean-Claude BJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK.
    Larroque-Lombard AL; Todorova M; Qiyu Q; Jean-Claude B
    Chem Biol Drug Des; 2011 May; 77(5):309-18. PubMed ID: 21294849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA.
    Brahimi F; Rachid Z; Qiu Q; McNamee JP; Li YJ; Tari AM; Jean-Claude BJ
    Int J Cancer; 2004 Nov; 112(3):484-91. PubMed ID: 15382076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2.
    Rachid Z; Macphee M; Williams C; Todorova M; Jean-Claude BJ
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5505-9. PubMed ID: 19665377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.
    Rachid Z; Brahimi F; Qiu Q; Williams C; Hartley JM; Hartley JA; Jean-Claude BJ
    J Med Chem; 2007 May; 50(11):2605-8. PubMed ID: 17472358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
    Matheson SL; McNamee JP; Wang T; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1163-70. PubMed ID: 15358812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
    Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
    Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41.
    Matheson SL; Brahimi F; Jean-Claude BJ
    Biochem Pharmacol; 2004 Mar; 67(6):1131-8. PubMed ID: 15006549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.